Dialog window

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
      • Natural Health Products
      • Topical OTC Drugs
      • Medical Devices
      • Consumer Products
      • FDA Consulting
    • Health Canada Consultants
      • Regulatory Affairs
      • Pharmacovigilance Services
      • MoCRA
      • Ingredient Compliance
      • CEPA
  • Innovation
  • Articles
  • Contact
Select Page
NNHPD Updates NHPID entries due to Benzene risk

NNHPD Updates NHPID entries due to Benzene risk

by Srishti Chaudhari | Apr 2, 2026 | Canadian Quality Assurance, Canadian Regulatory, Health Canada Updates, Natural Health Products

Following alerts from the US FDA regarding benzene contamination, the NNHPD has updated several entries in the NHPID. Benzene is a Class 1 solvent with unacceptable toxicity and must not be used in health product manufacturing. Key changes include the removal of...
Health Canada updates guidance on Adverse Reaction Reporting

Health Canada updates guidance on Adverse Reaction Reporting

by Srishti Chaudhari | Apr 2, 2026 | Canadian Quality Assurance, Canadian Regulatory, Health Canada Updates, Natural Health Products, Uncategorized

Health Canada has issued a notice clarifying adverse reaction reporting expectations for Market Authorization Holders (MAHs) of drugs (including pharmaceuticals, biologics and radiopharmaceuticals) and Natural Health Products (NHPs). The notice replaces Section 4.3 of...
Health Canada modernizes Medical Device Submission Requirements

Health Canada modernizes Medical Device Submission Requirements

by Srishti Chaudhari | Apr 2, 2026 | Canadian Regulatory, Health Canada Updates, Medical Device, Medical Devices

Health Canada has introduced several key regulatory updates in 2026 that significantly change how medical device applications are prepared and submitted. A major update is the new Guidance on Managing Applications for Medical Device Licenses (effective February 2,...
Health Canada ends FSRN Process

Health Canada ends FSRN Process

by Srishti Chaudhari | Feb 24, 2026 | Canadian Quality Assurance, Canadian Regulatory

A Foreign Site Reference Number (FSRN) is generally issued by Health Canada to foreign sites that manufacture, package, or label Natural Health Products (NHPs). It confirms partial compliance with GMP requirements under Part 3 of the NHP regulations. A FSRN is not...
New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA

New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA

by Srishti Chaudhari | Feb 13, 2026 | FDA, MoCRA, U.S. Regulatory

The U.S. Food and Drug Administration (FDA) has released a new draft guidance titled ‘Records Access for Cosmetics’. This publication marks another step in the ongoing implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Purpose and Scope:...
« Older Entries

Recent Posts

  • NNHPD Updates NHPID entries due to Benzene risk
  • Health Canada updates guidance on Adverse Reaction Reporting
  • Health Canada modernizes Medical Device Submission Requirements
  • New Compliance Requirements for the Canadian Domestic Substance List (DSL)
  • Health Canada ends FSRN Process

Recent Comments

    Archives

    • April 2026
    • February 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • June 2025
    • May 2025
    • March 2025
    • October 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • December 2023
    • November 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • January 2023
    • December 2022
    • November 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • October 2021
    • July 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • California Cosmetic Regulations
    • California Office of Environmental Health Hazard Assessment
    • Canadian Quality Assurance
    • Canadian Regulatory
    • Cosmetic Ingredient Hotlist
    • Cosmetics
    • Cosmetics
    • Environment and Climate Change Canada
    • European Regulatory
    • Events/Company Updates
    • FDA
    • Federal Plastics Registry
    • Health Canada Updates
    • Importation of NHPs
    • Innovation
    • Medical Device
    • Medical Devices
    • MoCRA
    • Natural Health Products
    • New Mexico
    • OTC Drugs
    • Our View
    • Prop 65
    • Research/Science/Technology
    • Toxic-Free Cosmetics Act
    • U.S. Regulatory
    • U.S. State Updates
    • Uncategorized
    Copyright © 2025 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY